AM109: A PSMA‑Targeted CD137 Bispecific Antibody for Metastatic Castration‑Resistant Prostate Cancer (mCRPC / mAPMR)

/in , /by

AM109 is designed as a bispecific agent that links a PSMA‑targeting humanized antibody to a CD137 (4‑1BB)‑targeting affibody, effectively creating a molecular bridge between prostate cancer cells and T cells in the tumor microenvironment. The rationale is straightforward: by restricting CD137 activation to sites where PSMA is expressed, the therapy aims to drive potent anti‑tumor […]

Read more

Astatine-211 PSMA-5: Scalable Alpha Therapy for Refractory Prostate Cancer

/in , , /by

211AtPSMA-5 emerges as a promising targeted alpha therapy for metastatic castration-resistant prostate cancer, particularly in patients who have exhausted standard treatments like androgen receptor pathway inhibitors, docetaxel, and cabazitaxel. This approach leverages astatine-211, a cyclotron-produced alpha emitter generated by bombarding abundant bismuth targets with alpha beams. The compound’s design mirrors established PSMA ligands such as […]

Read more

A nano-PROTAC on the horizon: combining targeted protein degradation and ferroptosis for advanced prostate cancer

/in , /by

A new study from Wuhan University and the Renmin Hospital of Wuhan University has reported a promising preclinical strategy for advanced prostate cancer, especially castration-resistant prostate cancer (CRPC). The work was published online in Angewandte Chemie International Edition, one of the leading international journals in chemistry. The study describes a new nano-PROTAC platform designed to […]

Read more

Deutenzalutamide in mCRPC: Meaningful Benefit in the HC‑1119‑04 Trial

/in , , /by

Nature reports the results of the HC‑1119‑04 trial, a randomized, multicenter, double‑blind, placebo‑controlled phase 3 study of deutenzalutamide (HC‑1119) in metastatic castration‑resistant prostate cancer (mCRPC) after treatment with abiraterone and docetaxel. The trial was conducted in China and enrolled 417 patients, with 276 randomized to deutenzalutamide 80 mg once daily and 141 to placebo. All […]

Read more

Scan Growth Without PSA Rise: Key Finding in Enzalutamide-Treated Prostate Cancer

/in /by

In a detailed review of two large clinical trials called ARCHES and PROSPER, doctors found that some patients experienced cancer growth visible on scans (known as radiographic progression) without seeing the usual rise in PSA blood levels, a key marker doctors often track. This mismatch highlights why regular imaging tests might be just as crucial […]

Read more

A New Drug Candidate TB511 Shows Promise for Hard-to-Treat Prostate Cancer

/in , /by

Castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, APMR) is one of the toughest forms of prostate cancer to treat. It becomes resistant to hormone therapy, and current immunotherapies don’t work well on it. The main reason is that CRPC tumors create an immune-“cold” environment filled with M2 macrophages, a type of immune […]

Read more

Darolutamide Monotherapy in ARAMON Trial: 52-Week Results in Non-Metastatic or Oligometastatic CSPC

/in , , , , /by

A new study called ARAMON shows promising results for using darolutamide alone to treat non-metastatic or oligometastatic castration-sensitive prostate cancer (CSPC), as known as androgen pathway modulator sensitive (APMS), in men who have biochemical recurrence after surgery or radiation. This phase 2 trial enrolled 23 evaluable patients with PSA ≥0.2 ng/mL post-prostatectomy or ≥2 ng/mL […]

Read more

EXS74539: A New LSD1 Inhibitor for Hard-to-Treat Solid Tumors, Including Prostate Cancer

/in , , /by

EXS74539, also called REC-4539, is an experimental cancer drug designed to block LSD1, a protein that helps some cancer cells grow and survive even when standard treatments fail. It is being tested in a phase 1 trial on people with selected solid tumors, including small-cell lung cancer, prostate cancer, ovarian cancer and others. This early-stage […]

Read more